The FDA approved 26 new treatments in 2009, the most in four years but only one more than in 2008, according to a Washington Analysis report. Blood thinner Effient, by Eli Lilly and Co. and Daiichi Sankyo, and Sanofi-Aventis' heart drug Multaq were among the approvals, while Novo Nordisk's liraglutide for diabetes and Amgen's osteoporosis drug denosumab failed to secure approval.

Related Summaries